RxDoctor Payments Data

Sarah Enlow

Family · Tell City, INNPI 1639838824

Payments from drug & device makers

$2,214in general payments, 2019–2025

Across 157 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$428
  • Urovant Sciences Inc$368
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$241
  • AbbVie$231
  • Axsome Therapeutics, Inc.$163
  • Alkermes, Inc.$134
  • plus $650 from 18 others

What the payments were for

  • Food & beverage$2,214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,214 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$175,830
Medicare patients
390
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$55,247
VraylarCariprazine Hcl27$34,294
TrulicityDulaglutide31$31,778
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen959$23,925
MyrbetriqMirabegron50$20,665
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog127$18,164
JardianceEmpagliflozin35$18,134
LinzessLinaclotide31$17,918
OxycontinOxycodone Hcl50$17,383
MovantikNaloxegol Oxalate54$15,727
AbrysvoRsv Vacc, Pref A And Pref B/Pf50$15,718
KeppraLevetiracetam13$15,158
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,103
GemtesaVibegron51$13,855
OzempicSemaglutide11$11,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Creon$231$61,89675 claims
Lilly USA, LLCTrulicity$16$31,77831 claims
Sumitomo Pharma America, Inc.Gemtesa$74$13,85551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Tell City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →